Consensus on diagnosis and management of Hereditary Angioedema in the Middle East: A Delphi initiative

Marcus Maurer 1 2, Mohamed Abuzakouk 3, Mona Al-Ahmad 4 5, Waleed Al-Herz 6, Hassan Alrayes 7, Salem Al-Tamemi 8, Rand Arnaout 7, Hend Binghadeer 9, Ravi Gutta 10, Carla Irani 11, Hassan Mobayed 12, Iman Nasr 13, Hiba Shendi 14, Fares Zaitoun 15

Affiliations

24 December 2022

-

doi: 10.1016/j.waojou.2022.100729

Abstract

Background: Hereditary angioedema (HAE), a potentially life-threatening genetic disorder due to C1 inhibitor deficiency in most cases, is characterized by sudden and/or recurrent attacks of angioedema (subcutaneous/submucosal swellings). The global World Allergy Organization (WAO)/European Academy of Allergy and Clinical Immunology (EAACI) International guideline for HAE management is comprehensive, but the implementation of this guideline may require regional adaptation considering the diversity in disease awareness, type of medical care systems, and access to diagnostics and treatment. The aim of this Delphi initiative was to build on the global guideline and provide regional adaptation to address the concerns and specific needs in the Middle East.

Methods: The Consensus panel comprised 13 experts from the Middle East (3 from the United Arab Emirates, 3 from Saudi Arabia, 2 from Lebanon, 2 from Kuwait, 2 from Oman and 1 from Qatar) who have more than 2 decades of experience in allergy and immunology and are actively involved in managing HAE patients. The process that was carried out to reach the consensus recommendation included: 1.) A systematic literature review for articles related to HAE management using Ovid MEDLINE. 2.) The development of a questionnaire by an internationally acclaimed expert, with 10 questions specific to HAE management in the Middle East. 3.) Experts received the questionnaire via email individually and their answers were recorded (email/interview). 4.) A virtual consensus meeting was organized to discuss the questionnaire, make amends if needed, vote, and achieve consensus.

Results: The questionnaire comprised 10 questions, each with 2 or more statements/recommendations on which the regional experts voted. A consensus was reached based on a 70% agreement between the participants. The key highlights include: 1) HAE experts in the Middle East emphasized the importance of a positive family history for arriving at a diagnosis of HAE. 2) The number of episodes per month or per 6-month period and severity should be used, together with other markers, to determine the need for prophylaxis. 3) Disease status should be monitored by periodic visits and the use of patient-reported outcome measures such as the angioedema activity score and the angioedema control test. 4) Attenuated androgens and tranexamic acid may be considered for long-term prophylaxis, if lanadelumab, C1-Inhibitor or berotralstat are not available.

Conclusion: This consensus recommendation may help to educate healthcare practitioners in the Middle East and unify their approach to the diagnosis and management of HAE.

Keywords: Delphi consensus; Hereditary angioedema; Middle east.

Similar articles

Consensus on treatment goals in hereditary angioedema: A global Delphi initiative.

Maurer M, Aygören-Pürsün E, Banerji A, Bernstein JA, Balle Boysen H, Busse PJ, Bygum A, Caballero T, Castaldo AJ, Christiansen SC, Craig T, Farkas H, Grumach AS, Hide M, Katelaris CH, Li HH, Longhurst H, Lumry WR, Magerl M, Martinez-Saguer I, Riedl MA, Zhi Y, Zuraw B.J Allergy Clin Immunol. 2021 Dec;148(6):1526-1532. doi: 10.1016/j.jaci.2021.05.016. Epub 2021 May 25.PMID: 34048855

Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema.

Anderson J, Maina N.Clin Transl Allergy. 2022 Jan 18;12(1):e12092. doi: 10.1002/clt2.12092. eCollection 2022 Jan.PMID: 35079346 Free PMC article. Review.

The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.

Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygören-Pürsün E, Banerji A, Bara NA, Boccon-Gibod I, Bork K, Bouillet L, Boysen HB, Brodszki N, Busse PJ, Bygum A, Caballero T, Cancian M, Castaldo AJ, Cohn DM, Csuka D, Farkas H, Gompels M, Gower R, Grumach AS, Guidos-Fogelbach G, Hide M, Kang HR, Kaplan AP, Katelaris CH, Kiani-Alikhan S, Lei WT, Lockey RF, Longhurst H, Lumry W, MacGinnitie A, Malbran A, Martinez Saguer I, Matta Campos JJ, Nast A, Nguyen D, Nieto-Martinez SA, Pawankar R, Peter J, Porebski G, Prior N, Reshef A, Riedl M, Ritchie B, Sheikh FR, Smith WB, Spaeth PJ, Stobiecki M, Toubi E, Varga LA, Weller K, Zanichelli A, Zhi Y, Zuraw B, Craig T.World Allergy Organ J. 2022 Apr 7;15(3):100627. doi: 10.1016/j.waojou.2022.100627. eCollection 2022 Mar.PMID: 35497649 Free PMC article.

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update.

Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygören-Pürsün E, Banerji A, Bara NA, Boccon-Gibod I, Bork K, Bouillet L, Boysen HB, Brodszki N, Busse PJ, Bygum A, Caballero T, Cancian M, Castaldo A, Cohn DM, Csuka D, Farkas H, Gompels M, Gower R, Grumach AS, Guidos-Fogelbach G, Hide M, Kang HR, Kaplan AP, Katelaris C, Kiani-Alikhan S, Lei WT, Lockey R, Longhurst H, Lumry WR, MacGinnitie A, Malbran A, Martinez Saguer I, Matta JJ, Nast A, Nguyen D, Nieto-Martinez SA, Pawankar R, Peter J, Porebski G, Prior N, Reshef A, Riedl M, Ritchie B, Rafique Sheikh F, Smith WB, Spaeth PJ, Stobiecki M, Toubi E, Varga LA, Weller K, Zanichelli A, Zhi Y, Zuraw B, Craig T.Allergy. 2022 Jul;77(7):1961-1990. doi: 10.1111/all.15214. Epub 2022 Feb 3.PMID: 35006617

The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency.

Jacobs J, Neeno T.Postgrad Med. 2021 Aug;133(6):639-650. doi: 10.1080/00325481.2021.1905364. Epub 2021 Jul 6.PMID: 33993830 Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Goldman L., Schafer A. 2011. Goldman's Cecil medicine E-book.https://books.google.com/books?hl=en&lr=&id=8y7nLY_5PFEC&oi=fnd&pg=PP1&d...
  2.  
    1. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema A broad review for clinicians. https://jamanetwork.com/. - PubMed
  3.  
    1. Gompels M.M., Lock R.J., Abinun M., et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139(3):379–394. doi: 10.1111/J.1365-2249.2005.02726.X. - DOI - PMC - PubMed
  4.  
    1. Talavera A., Larraona J.L., Ramos J.L., et al. Hereditary angioedema: an infrequent cause of abdominal pain with ascites. Am J Gastroenterol. 1995;90(3):471–474. http://europepmc.org/abstract/MED/7872288 - PubMed
  5.  
    1. World Population Prospects (2022 Revision). United Nations population estimates and projections. https://worldpopulationreview.com/continents/the-middle-east-population. Accessed September 29, 2022.
  6.  
    1. Davis A.E., III. The pathogenesis of hereditary angioedema. Transfus Apher Sci. 2003;29:195–203. - PubMed
  7.  
    1. Zuraw B.L. Diagnosis and management of hereditary angioedema: an American approach. Transfus Apher Sci. 2003;29(3):239–245. doi: 10.1016/j.transci.2003.08.008. - DOI - PubMed
  8.  
    1. Agostoni A., Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltim) 1992;71(4):206–215. doi: 10.1097/00005792-199207000-00003. - DOI - PubMed
  9.  
    1. Donaldson V.H., Evans R.R. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C′1-esterase. Am J Med. 1963;35(1):37–44. doi: 10.1016/0002-9343(63)90162-1. - DOI - PubMed
  10.  
    1. Rosen F.S., Alper C.A., Pensky J., Klemperer M.R., Donaldson V.H. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest. 1971;50(10):2143–2149. doi: 10.1172/JCI106708. - DOI - PMC - PubMed
  11.  
    1. Binkley K.E., Davis A.E., III Estrogen-dependent inherited angioedema. Transfus Apher Sci. 2003;29(3):215–219. doi: 10.1016/j.transci.2003.08.002. - DOI - PubMed
  12.  
    1. Binkley K.E., Davis A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106(3):546–550. doi: 10.1067/mai.2000.108106. - DOI - PubMed
  13.  
    1. Bork K., Barnstedt S.-E., Koch P., Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356(9225):213–217. doi: 10.1016/S0140-6736(00)02483-1. - DOI - PubMed
  14.  
    1. Chen M., Riedl M.A. Emerging therapies in hereditary angioedema. Immunol Allergy Clin. 2017;37(3):585–595. doi: 10.1016/j.iac.2017.03.003. - DOI - PMC - PubMed
  15.  
    1. Farkas H. Hereditary angioedema: examining the landscape of therapies and preclinical therapeutic targets. Expert Opin Ther Targets. 2019;23(6):457–459. doi: 10.1080/14728222.2019.1608949. - DOI - PubMed
  16.  
    1. James C., Bernstein J.A. Current and future therapies for the treatment of histamine-induced angioedema. Expet Opin Pharmacother. 2017;18(3):253–262. doi: 10.1080/14656566.2017.1282461. - DOI - PMC - PubMed
  17.  
    1. Maurer M., Magerl M., Ansotegui I., et al. The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. World Allergy Organ J. 2018;11:5. doi: 10.1186/s40413-017-0180-1. - DOI - PMC - PubMed
  18.  
    1. Hernández Fernandez de Rojas D., Ibañez E., Longhurst H., et al. Treatment of HAE attacks in the icatibant outcome survey: an analysis of icatibant self-administration versus administration by Health care professionals. Int Arch Allergy Immunol. 2015;167(1):21–28. doi: 10.1159/000430864. - DOI - PubMed
  19.  
    1. Maurer M., Aygören-Pürsün E., Banerji A., et al. Consensus on treatment goals in hereditary angioedema: a global Delphi initiative. J Allergy Clin Immunol. 2021;148(6):1526–1532. doi: 10.1016/j.jaci.2021.05.016. - DOI - PubMed
  20.  
    1. Association W.M. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi: 10.1001/jama.2013.281053. - DOI - PubMed
  21.  
    1. Maurer M., Aberer W., Agondi R., et al. Definition, aims, and implementation of ga2len/HAEi angioedema centers of reference and excellence. Allergy Eur J Allergy Clin Immunol. 2020;75(8) doi: 10.1111/ALL.14293. - DOI - PubMed
  22.  
    1. Zahedi R., Bissler J.J., Davis A.E., Andreadis C., Wisnieski J.J. Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-->Val substitution and functional analysis of the recombinant mutant protein. J Clin Invest. 1995;95(3):1299–1305. doi: 10.1172/JCI117780. - DOI - PMC - PubMed
  23.  
    1. Zuraw B.L. Hereditary angioedema. N Engl J Med. 2008;359(10):1027–1036. doi: 10.1056/NEJMcp0803977. - DOI - PubMed
  24.  
    1. Cicardi M., Suffritti C., Perego F., Caccia S. Novelties in the diagnosis and treatment of angioedema. J Investig Allergol Clin Immunol. 2016;26(4):212–221. doi: 10.18176/jiaci.0087. - DOI - PubMed
  25.  
    1. Bouillet L., Longhurst H., Boccon-Gibod I., et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199(5):484.e1–484.e4. doi: 10.1016/j.ajog.2008.04.034. - DOI - PubMed
  26.  
    1. Zotter Z., Csuka D., Szabó E., et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2014;9(1) doi: 10.1186/1750-1172-9-44. - DOI - PMC - PubMed
  27.  
    1. Martinez-Saguer I., Rusicke E., Aygören-Pürsün E., Heller C., Klingebiel T., Kreuz W. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol. 2010;203(2):131.e1–131.e7. doi: 10.1016/j.ajog.2010.03.003. - DOI - PubMed
  28.  
    1. Bowen T., Cicardi M., Farkas H., et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24. doi: 10.1186/1710-1492-6-24. - DOI - PMC - PubMed
  29.  
    1. Czaller I., Visy B., Csuka D., Füst G., Tóth F., Farkas H. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):44–49. doi: 10.1016/j.ejogrb.2010.05.008. - DOI - PubMed
  30.  
    1. Wahn V., Aberer W., Eberl W., et al. Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies. Eur J Pediatr. 2012;171(9):1339–1348. doi: 10.1007/s00431-012-1726-4. - DOI - PMC - PubMed
  31.  
    1. Kreuz W., Rusicke E., Martinez-Saguer I., Aygören-Pürsün E., Heller C., Klingebiel T. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion. 2012;52(1):100–107. doi: 10.1111/j.1537-2995.2011.03240.x. - DOI - PubMed
  32.  
    1. Cicardi M., Banerji A., Bracho F., et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532–541. doi: 10.1056/NEJMoa0906393. - DOI - PMC - PubMed
  33.  
    1. Busse P.J., Farkas H., Banerji A., et al. Lanadelumab for the prophylactic treatment of hereditary angioedema with C1 inhibitor deficiency: a review of preclinical and phase I studies. BioDrugs. 2019;33(1):33–43. doi: 10.1007/s40259-018-0325-y. - DOI - PMC - PubMed
  34.  
    1. Mathis A., Sale M., Cornpropst M., Sheridan W.P., Ma S.C. Population pharmacokinetic modeling and simulations of berotralstat for prophylactic treatment of attacks of hereditary angioedema. Clin Transl Sci. 2022;15(4):1027–1035. doi: 10.1111/cts.13233. - DOI - PMC - PubMed

Page Navigation